Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

ProMIS moving ahead with vaccine against toxic alpha-synuclein

ProMIS Neurosciences announced arriving at a lead candidate vaccine against the misfolded alpha-synuclein protein, which the company plans to develop as a treatment for Parkinson’s disease and related disorders. The potential vaccine, known as PMN400, is moving into preclinical testing in animal models of Parkinson’s. “We are…

Air pollution amplifies Parkinson’s risk when genetics also a factor

Air pollution may increase the risk of Parkinson’s disease, particularly in people who are already genetically predisposed to develop the disorder, a study shows. “We discovered that individuals with elevated genetic susceptibility and heightened exposure to air pollutants faced a markedly heightened risk of [Parkinson’s],” its researchers wrote. “Therefore,…

FDA approves new DBS device from Medtronic

The U.S. Food and Drug Administration (FDA) has approved Medtronic‘s Percept RC deep brain stimulation (DBS) system, clearing it for use to treat Parkinson’s disease and other movement disorders. DBS is a surgical procedure in which an electrode is implanted in the brain to provide electrical stimulation…